Biotechnology

Cyclerion Therapeutics

Cyclerion Therapeutics released FY2025 9 Months Earnings on November 12 EST, with actual revenue of USD 1.049 M and EPS of USD -0.9672

Cyclerion Therapeutics released FY2025 Q3 earnings on November 12, 2025, with actual revenue of USD 875 K and EPS of USD -0.3026

Cyclerion Therapeutics released FY2025 Q2 earnings on August 5 (EST), actual revenue USD 93K, actual EPS USD -0.1055

Cyclerion Therapeutics released FY2025 Semi-Annual Earnings on August 5, 2025 (EST), with actual revenue of USD 174K and EPS of USD -0.6168

Cyclerion Therapeutics Signs $20 Million Sales Agreement with Guggenheim Securities

Cyclerion Therapeutics released FY2025 Q1 earnings on May 6 (EST), actual revenue USD 81K, actual EPS USD -0.559

Cyclerion Therapeutics released FY2024 earnings on March 4, 2025 (EST), actual revenue 2 M USD (forecast 0 USD), actual EPS -1.214 USD (forecast -30 USD)

Cyclerion Therapeutics released FY2024 Q4 earnings on March 4, 2025 (EST), with actual revenue of 1.806 M USD and EPS of 0.2084 USD

Cyclerion Therapeutics released FY2024 9 Months Earnings on November 14 (EST), with actual revenue of USD 194K and EPS of USD -1.4311

Cyclerion Therapeutics released FY2024 Q3 earnings on November 14 EST, actual revenue USD 194 K, actual EPS USD -0.2862

Cyclerion Therapeutics released FY2024 Q2 earnings on August 7 (EST) with actual revenue of USD 0 and EPS of USD -0.5266

Cyclerion Therapeutics released FY2023 Q4 earnings on March 5, 2024 (EST), with actual revenue of USD 0 and EPS of USD -0.6907 (forecast EPS was USD -7.4)

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

Gulf Resources

DigitalBridge

Toro

Dreamland

Lichen

Springview

Alumis

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap